Ampio Pharmaceuticals IncOOTC AMPE Stock Report

Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Englewood, Colorado and currently employs 21 full-time employees. The company went IPO on 2011-05-19. The firm's lead product candidate, Ampion has immunomodulatory action and anti-inflammatory effects, which provide a treatment for individuals with inflammatory conditions including, but not limited to, severe osteoarthritis of the knee (OAK); osteoarthritis related to other joints, such as hip, shoulder, ankle and hand; and the widespread inflammation associated with COVID-19 infection. Ampion is in development as an intra-articular injection treatment for severe OAK, an intravenous (IV) and inhaled treatment for hospitalized severe and/or critical COVID-19 patients, and an at-home inhalation treatment for patients with prolonged respiratory symptoms due to COVID-19, referred to as Long-COVID. Its clinical studies include AP-013, AP-017, AP-019 and AP-018.